However, persistent or severe symptoms warrant medical review to exclude other gastrointestinal pathology, including pancreatitis or gallbladder disease, which are recognised risks with GLP-1 receptor agonists according to the MHRA/EMC Summary of Product Characteristics
Rus GZ, Jansen K, Titus S, Carvalho AF, Gabbay V, Quevedo J (2015) Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies
"A lot more needs to be done to regulate this space," Dr Yip said
doi: 10.3164/jcbn.1106SR 104 MollFWalterMRezendeFHelfingerVVasconezEDe OliveiraTet al
The non-inferiority margin used was a HR of 1.8, which was considered inappropriate by Health Canada 11 as 1.3 is the recommended
Formulations, concentrations, additives, and beyond-use dating may vary between compounding pharmacies